Develops precision neuroscience drugs targeting receptor-associated proteins for epilepsy and neurological pain.
Develops precision neuroscience drugs targeting receptor-associated proteins for epilepsy and neurological pain.
Has no product on sale, so it funds trials with capital raised from investors, including a 2024 stock-market debut. Any revenue would start with approval of its lead epilepsy drug, or earlier from a licensing deal with a larger drugmaker.
Moat: none (IP / patents). Novel receptor-associated-protein targeting approach spun from prior pharma research, but still clinical-stage.
Headquarters: Boston, Massachusetts, US · Founded: 2022 · Employees: 84
Size Rapport Therapeutics (RAPP) is a United States Health Care company (Biotechnology) with a market value of $1.39B, the 2025th largest of 3,085 United States companies the cockpit tracks. Shares closed at $23.40 on 18 Nov 2026.
Performance Over six months the shares fell 34.5%, against -17.2% for the median peer and -2.2% for the United States market (cap-weighted) — 4th lowest of 19 in its peer set.
Growth The operating margin is -838.1% (peer median -178.1%).
Valuation It trades at 50.1× enterprise value to sales against a peer median of 21.3× (8th most expensive of 18).
Short interest Short interest is 6.7% of the free float (30 Oct 2026).
Next results Next results expected around 16 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $20.0M | $0 | $0 | $0 | $0 |
| Revenue growth | — | — | — | — | — |
| Gross profit | $19.1M | -$1.02M | -$839,000 | -$112,000 | -$15,000 |
| EBITDA | -$167M | -$124M | -$82.2M | -$36.1M | -$10.4M |
| Net income | -$150M | -$111M | -$78.3M | -$34.8M | -$10.7M |
| Free cash flow | -$121M | -$88.1M | -$67.2M | -$28.8M | -$3.53M |
| Capital expenditure | $333,000 | $616,000 | $2.40M | $1.64M | $284,000 |
| Total debt | $9.39M | $11.5M | $1.48M | $2.15M | $0 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Rapport Therapeutics RAPP | $1.39B | -34% | n/a | -838% | 50.1× | n/a |
| Xenon Pharmaceuticals XENE | $3.71B | -31% | -100% | n/a | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | RAPP | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -20.3% | -14.8% | 4th lowest of 21 |
| 6-month return | -34.5% | -17.2% | 4th lowest of 19 |
| Distance from 52-week high | -55.8% | -46.1% | 6th lowest of 21 |
| Operating margin | -838.1% | -178.1% | 5th lowest of 19 |
| EV / Sales | 50.1× | 21.3× | 8th most expensive of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Rapport Therapeutics RAPP | United States | $1.39B | -34% | n/a | -838% | 50.1× | n/a | n/a |
| CanSino Biologics 688185.SS | China | $1.38B | 0% | +30% | -4% | 6.6× | n/a | n/a |
| AnaptysBio ANAB | United States | $1.40B | -22% | +13% | 62% | 7.9× | 0.5% | +25.6% |
| Oncolys BioPharma 4588.T | Japan | $1.37B | +181% | +1,749% | -295% | 408.9× | n/a | n/a |
| Intellia Therapeutics NTLA | United States | $1.37B | -20% | -8% | -821% | 21.3× | n/a | n/a |
| Absci ABSI | United States | $1.41B | +65% | -47% | -9,155% | 835.7× | n/a | n/a |
| Tyra Bioscience TYRA | United States | $1.35B | -41% | n/a | n/a | n/a | n/a | n/a |
| uniQure QURE | United States | $1.42B | -17% | +28% | -1,027% | 65.4× | n/a | n/a |
| Nanjing Vazyme Biotech 688105.SS | China | $1.42B | +25% | +16% | -5% | 4.9× | 39.4% | -2.5% |
| Generate Biomedicines GENB | United States | $1.34B | -20% | +56% | -737% | 31.7× | n/a | n/a |
| Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCR | United States | $1.44B | -7% | +13% | -7% | 2.3× | n/a | n/a |
| Nuvation Bio NUVB | United States | $1.34B | -16% | +654% | -61% | 5.7× | n/a | n/a |
| Wuhan Healthgen Biotechnology 688765.SS | China | $1.46B | -51% | +90% | -297% | 205.0× | n/a | n/a |
| Zhuhai Trinomab Pharmaceutical 688806.SS | China | $1.32B | n/a | +238% | -1,196% | 164.8× | n/a | n/a |
| UroGen Pharma URGN | United States | $1.46B | -1% | +159% | -12% | 6.3× | n/a | n/a |
| Novavax NVAX | United States | $1.31B | -14% | -61% | -17% | 2.4× | n/a | n/a |
| Fujian Haixi Pharmaceuticals 2637.HK | Hong Kong | $1.47B | -32% | +25% | 33% | n/a | n/a | n/a |
| Taysha Gene Therapies TSHA | United States | $1.30B | -27% | -13% | -2,998% | 170.1× | n/a | n/a |
| Mesoblast MSB.AX | Australia | $1.49B | -17% | +556% | -43% | 12.8× | n/a | n/a |
| Peptron 087010.KS | South Korea | $1.49B | -68% | -13% | -488% | 359.6× | n/a | n/a |
| TLC BioSciences 7924.TWO | Taiwan | $1.50B | n/a | n/a | n/a | n/a | n/a | n/a |